An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

This study has been completed.

First Received: August 31, 2006 Last Updated: June 12, 2008 History of Changes

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00371813

Purpose

To investigate safety and efficacy of varenicline tartrate in helping people quit smoking

Condition	Intervention	Phase
Smoking Cessation	Drug: Varenicline tartrate Drug: Placebo	Phase III

MedlinePlus related topics: Quitting Smoking Smoking

Drug Information available for: Varenicline Varenicline tartrate

Study Type:	Interventional
Study Design:	Double-Blind, Parallel Assignment, Placebo Control, Randomized, Safety/Efficacy Study, Treatment
Official Title:	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Multinational Study Of Efficacy And Safety Of Varenicline Tartrate For Smoking Cessation

Further study details as provided by Pfizer:

Primary Outcome Measures:

To compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation, and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.

Secondary Outcome Measures:

To gather safety data for 12 weeks of treatment with varenicline 1 mg BID or placebo followed by 12 weeks of non-treatment follow-up.

Eligibility

Criteria

Inclusion Criteria:

Current cigarette smokers between the ages of 18 and 75 years, who are motivated to stop smoking

Exclusion Criteria:

Patients currently suffering from depression, or have been diagnosed with depression in the last 12 months, or subjects with past or present history of psychosis, panic disorder, or bipolar disorder
Any subject with known severe chronic obstructive pulmonary disease (COPD)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00371813

Locations

China
Pfizer Investigational Site
Beijing, China, 100020
Pfizer Investigational Site
Shanghai, China, 200233
Pfizer Investigational Site
Tanjin, China, 300052
Pfizer Investigational Site
Beijing, China, 100036
Pfizer Investigational Site
Beijing, China, 100853
Pfizer Investigational Site
Guangzhou, China, 510120
Pfizer Investigational Site
Beijing, China, 100029
China, Liao Ning
Pfizer Investigational Site
Shen Yang, Liao Ning, China, 110001
China, Liaoning
Pfizer Investigational Site
Shenyang, Liaoning, China, 110016
Singapore
Pfizer Investigational Site
Singapore, Singapore, 169608
Pfizer Investigational Site
Singapore, Singapore, 228310
Pfizer Investigational Site
Singapore, Singapore, 159964
Thailand
Pfizer Investigational Site
Bangkok, Thailand, 10330
Pfizer Investigational Site
Chiang Mai, Thailand, 50200

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

Link to ClinicalStudyResults.org Posting This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	A3051055
Study First Received:	August 31, 2006
Last Updated:	June 12, 2008
ClinicalTrials.gov Identifier:	NCT00371813 History of Changes
Health Authority:	China: State Food and Drug Administration

Study placed in the following topic categories:

Smoking

Additional relevant MeSH terms:

Habits
Smoking

ClinicalTrials.gov processed this record on March 16, 2009